CCRM supports the commercialization of regenerative medicine-based technologies, and cell and gene therapies, with strategic funding, dedicated infrastructure and specialized business and scientific expertise.

By partnering with leading research institutions to launch new ventures, enabling industry by providing innovative contract development and manufacturing organization (CDMO) services, and scaling emerging companies by catalyzing investment, CCRM is accelerating the translation of promising technologies, processes and therapies into life-changing health outcomes for patients.

Established in 2011, CCRM is a Canadian not-for-profit organization funded by the Government of Canada, the Province of Ontario, and leading academic and industry partners.
A network of researchers, leading companies, strategic investors and entrepreneurs, CCRM accelerates the translation of scientific discovery into new companies and marketable products for patients, with specialized teams, funding, and infrastructure. CCRM is the commercialization partner of Medicine by Design and is hosted by the University of Toronto. In 2021, we celebrated our 10-year anniversary. Catch up on our story so far by reading “The CCRM story: 10 years in the making,” on the Innovations of the World website.

How CCRM is building a sustainable cell and gene therapy ecosystem

Presented by Michael May, PhD, President and CEO of CCRM, this video provides an overview of how CCRM is building a sustainable cell and gene therapy ecosystem by catalyzing manufacturing capability, access to capital and talent development.
Located in Toronto’s Discovery District, CCRM is in the heart of Canada’s premier health care innovation hub, and is surrounded by over 30 world-class clinical and research institutions. With access to more than 140,000 students and scientists in Toronto, CCRM is deeply interconnected in a thriving biomedical cluster.